Rozanolixizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric/humanized hybrid |
| Target | Neonatal Fc receptor (FCGRT) |
| Clinical data | |
| Trade names | Rystiggo |
| Other names | UCB-7665, rozanolixizumab-noli |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623040 |
| License data | |
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6462H9984N1704O2016S44 |
| Molar mass | 145211.51 g·mol−1 |
Rozanolixizumab, sold under the brand name Rystiggo, is a monoclonal antibody used for the treatment of myasthenia gravis. Rozanolixizumab is a humanized and chimeric monoclonal antibody; and is a neonatal Fc receptor blocker.
The most common adverse reactions include headache, infections, diarrhea, pyrexia, hypersensitivity reactions, and nausea.
Rozanolixizumab was approved for medical use in the United States in June 2023, and in the European Union in January 2024.